Surgery Partners, Inc. (NASDAQ:SGRY – Get Free Report) Director Teresa Deluca acquired 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was acquired at an average cost of $14.35 per share, with a total value of $143,500.00. Following the completion of the acquisition, the director directly owned 66,843 shares in the company, valued at approximately $959,197.05. This represents a 17.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Surgery Partners Price Performance
Surgery Partners stock traded down $0.64 during trading hours on Wednesday, hitting $13.60. 2,090,076 shares of the company traded hands, compared to its average volume of 1,568,358. The firm’s 50-day simple moving average is $15.62 and its two-hundred day simple moving average is $14.40. The company has a quick ratio of 1.78, a current ratio of 1.95 and a debt-to-equity ratio of 1.18. The firm has a market cap of $1.78 billion, a P/E ratio of -19.43, a P/E/G ratio of 4.08 and a beta of 1.92. Surgery Partners, Inc. has a 1-year low of $11.41 and a 1-year high of $24.10.
Surgery Partners (NASDAQ:SGRY – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.04. Surgery Partners had a negative net margin of 2.63% and a positive return on equity of 0.88%. The firm had revenue of $848.90 million for the quarter, compared to analyst estimates of $830.03 million. During the same quarter in the previous year, the business posted $0.17 earnings per share. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. As a group, analysts forecast that Surgery Partners, Inc. will post 0.25 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Surgery Partners
Analyst Upgrades and Downgrades
SGRY has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Surgery Partners in a report on Tuesday, May 26th. Raymond James Financial set a $18.00 price objective on shares of Surgery Partners in a research note on Tuesday, August 11th. TD Cowen lifted their price objective on shares of Surgery Partners from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Jefferies Financial Group reissued a “buy” rating and set a $17.00 target price on shares of Surgery Partners in a research note on Wednesday, May 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 target price on shares of Surgery Partners in a report on Tuesday, August 11th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Surgery Partners currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.45.
View Our Latest Stock Report on SGRY
About Surgery Partners
Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.
Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.
Read More
- Five stocks we like better than Surgery Partners
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.
